In:
Hepatology Research, Wiley, Vol. 44, No. 10 ( 2014-10)
Abstract:
We sought to clarify the associations between serum cytokines and chemokines, hepatitis B surface antigen ( HBsAg ), hepatitis B core‐related antigen ( HBcrAg ), and hepatitis B virus ( HBV ) DNA and response to entecavir therapy in chronic hepatitis B . Methods We analyzed six cytokines (interleukin [ IL ]‐2, IL ‐6, IL ‐10, IL ‐12p70, IL ‐21 and IL ‐22) and five chemokines ( CCL2 , CCL3 , CXCL9 , CXCL10 and CXCL11 ) before and at 6, 12 and 24 months during entecavir therapy in 48 chronic hepatitis B patients. Quantitative measurement of HBsAg , HBcrAg and HBV DNA was performed. A virological response ( VR ) was defined as serum HBV DNA of less than 2.1 log copies/mL by treatment month 24. Results Thirty‐nine patients (81%) achieved a VR . Serum IL ‐6 ( P = 0.031), CXCL ‐9 ( P = 0.002), and CXCL ‐10 ( P = 0.001) were high in chronic HBV and correlated positively with transaminases and bilirubin. Before treatment, elevated IL ‐22 ( P = 0.031) and lower HBsAg ( P = 0.001) and HBcrAg ( P 〈 0.001), but not HBV DNA , were associated with a favorable treatment outcome. In multivariate analysis, high IL ‐22 (hazard ratio = 13.67, P = 0.046) and low HBcrAg (hazard ratio = 10.88, P = 0.048) were independently associated with a VR . The levels of IL ‐22 ( P 〈 0.001), HBsAg ( P 〈 0.001), and HBcrAg ( P 〈 0.001) all decreased from baseline to 24 months of treatment in virological responders. Conclusion Serum IL ‐22 and HBcrAg are predictive markers of a VR to entecavir therapy in patients with chronic hepatitis B .
Type of Medium:
Online Resource
ISSN:
1386-6346
,
1872-034X
DOI:
10.1111/hepr.2014.44.issue-10
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2006439-1
Permalink